Gram Negative Bacteria

Patients previously treated with trimethoprim-sulfamethoxazole for Stenotrophomonas maltophilia may require alternative therapies because of high rates of resistance to the agent, according to a review examining the epidemiology of the infection.

A review of the initial use of seven new antimicrobial agents at six community hospitals in western Pennsylvania revealed that uptake occurred within 1 to 2 years of FDA approval, and researchers observed that ceftolozane-tazobactam and ceftazidime-avibactam were more frequently chosen for off-label use.